European Commission approves epcoritamab with lenalidomide and rituximab for follicular lymphoma
The European Commission granted marketing authorization for epcoritamab (Tepkinly) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, based on Phase 3 EPCORE FL-1 data. In the randomized trial (n=243 combination, n=245 control) the combination reduced risk of progression or death by 79% (HR 0.21), produced a 96% overall response rate and 74% complete response rate versus 81% ORR and 43% CR with lenalidomide and rituximab alone. The approval establishes a chemotherapy-free, bispecific-based second-line option in Europe while safety signals included serious adverse reactions in 44% of combination-treated patients.
The EC approved epcoritamab with lenalidomide and rituximab for R/R follicular lymphoma.
Context
A Phase 3 trial compared epcoritamab plus lenalidomide and rituximab to lenalidomide and rituximab alone. The trial showed much higher response rates and lower progression risk. Regulators may now review wider use and longer-term safety…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked